Chromatography method
The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.
1. A method for purification of immunoglobulin containing proteins or parts thereof, from contaminants that are larger than immunoglobulin containing proteins, the method comprising:
a) contacting an immunoglobulin containing sample with agarose chromatography beads comprising a lid consisting of agarose modified with hydrolyzed allyl groups and having a thickness of 1-8 μm with a defined pore size and an inner core of defined pore size consisting of agarose modified with an affinity ligand;
b) adsorbing the immunoglobulin containing proteins to the ligands;
c) washing the beads to remove any contaminants; and
d) eluting the beads to release the captured immunoglobulin containing proteins or parts thereof.
2. The method of claim 1 , wherein the contaminants are virus.
3. The method of claim 1 , wherein the average diameter size of the chromatography bead is 10-500 μm.
4. The method of claim 1 , wherein the thickness of the lid is 3-5 μm.
5. The method of claim 1 , wherein the pore size of the lid and core correspond to Kd of 0.1 to 1.
6. The method of claim 1 , wherein the porosity of the lid and core is 0.30 to 0.95.
7. The method of claim 1 , wherein the affinity ligand is a proteinaceus affinity ligand.
8. The method of claim 1 , wherein the ligand is Protein A or affinity ligand derived from Protein A.
9. The method of claim 1 , wherein the immunoglobulin containing protein is a mAb.
10. The method of claim 1 , wherein the affinity ligand is Protein L or an affinity ligand derived from Protein L.
11. The method of claim 1 , wherein the immunoglobulin is a Fab.
12. The method of claim 1 , wherein the affinity ligand is Protein G or an affinity ligand derived from Protein G.
13. The method of claim 1 , wherein the chromatography beads are provided in a column and the contaminants are obtained in the flow through.
14. The method of claim 1 , wherein the chromatography beads are provided in a batch mode.
15. The method of claim 1 , wherein the chromatography beads are magnetic.
16. The method of claim 1 , wherein the chromatography beads are provided in fluidised bed mode.
17. The method of claim 1 , which is used in a validation process for obtaining therapeutic immunoglobulins substantially free from contaminating virus.
18. A method for purification of immunoglobulin containing proteins or parts thereof from virus, the method comprising:
a) contacting an immunoglobulin containing sample with chromatography beads comprising a lid having a thickness of 3-5 μm with a defined pore size and an inner core of defined pore size provided with protein Z4 ligand;
b) adsorbing the immunoglobulin containing proteins to the ligands;
c) washing the beads to remove any virus; and
d) eluting the beads to release the captured immunoglobulin containing proteins or parts thereof, which are substantially free from contaminating virus,
wherein the average diameter size of the chromatography bead is 250-450 μm,
wherein the pore size of the lid and core correspond to K D of about 0.3 to 0.7,
wherein the porosity of the lid and core is 0.60 to 0.85, and
wherein the lid and core are made of agarose.
19. The method of claim 18 , wherein the lid consists of agarose modified by hydrolyzed allyl groups.
20. The method of claim 18 , wherein the immunoglobulin containing protein is a mAb.
21. The method of claim 18 , wherein the immunoglobulin is a Fab.
22. The method of claim 18 , wherein the chromatography beads are provided in a column.
23. The method of claim 18 , wherein the chromatography beads are provided in a batch mode.
24. The method of claim 18 , wherein the chromatography beads are magnetic.
25. The method of claim 18 , wherein the chromatography beads are provided in fluidised bed mode.
26. The method of claim 18 , which is used in a validation process for obtaining therapeutic immunoglobulins substantially free from contaminating virus.